|1.||Hamblin, Michael R: 10 articles (02/2015 - 09/2007)|
|2.||Zhou, Zhiguo: 8 articles (01/2015 - 12/2009)|
|3.||Kepley, Christopher L: 7 articles (01/2015 - 07/2007)|
|4.||Aoshima, Hisae: 6 articles (11/2015 - 06/2010)|
|5.||Chiang, Long Y: 6 articles (02/2015 - 12/2011)|
|6.||Popov, Alexey A: 5 articles (11/2015 - 12/2006)|
|7.||Huang, Ying-Ying: 5 articles (02/2015 - 12/2011)|
|8.||Zhang, Zhenzhong: 5 articles (01/2015 - 01/2013)|
|9.||Da Ros, Tatiana: 5 articles (01/2015 - 07/2011)|
|10.||Sharma, Sulbha K: 5 articles (09/2014 - 12/2011)|
08/01/2014 - "This study investigates the role and mechanism of action of fullerenes in deactivating mast cell-based inflammation, paving the way to the development of a novel, non-steroid therapy in reactive airway disease."
01/01/2010 - "These data in intratracheal instillation and inhalation studies suggested that well-dispersed fullerenes do not have strong potential of neutrophil inflammation."
12/01/2011 - "These results suggest that different hydroxylation of fullerenes caused no cytotoxicity or inflammation up to 8.55 μg/ml. These findings suggest that extrapolation across similar NP will be dependent upon surface chemistry and concentration which may affect the degree of agglomeration and thus biological effects."
12/01/2009 - "We show that PMA-induced inflammation and oedema is dramatically inhibited when fullerenes are given prior to challenge. "
10/01/2012 - "These data suggest that laser-induced inflammation is suppressed by the ROS-scavenging activity of fullerene and that application of fullerene is effective against oxidative skin damage caused by laser irradiation. "
02/25/2013 - "This study provides useful insights into designing and improving the applicability of fullerene for other targeted cancer prodrug systems."
09/22/2009 - "In the present study, we report the novel application of polyhydroxylated fullerenes (fullerenols) in cancer drug delivery. "
08/15/2014 - "To evaluate potential novel anti-tumor compounds against KSHV-associated PEL, seven water-soluble fullerene derivatives were evaluated as potential drug candidates for the treatment of PEL. "
07/01/2014 - "A fullerene-based multi-functional nanoplatform for cancer theranostic applications."
06/01/2014 - "To clarify the intra tumor distribution of gadlinium containing fullerene (Gd@C82), micro particle induced X-ray emission (Micro-PIXE) analysis were performed. "
02/01/2013 - "The composite nanofibers used as substrates for bioimaging in vitro were evaluated with human liver carcinoma HepG2 cells, the fullerene nanoparticles signal almost displayed in every cell, implying the potential of fluorescent fullerene nanoparticles/PLLA nanofibers to be used as scaffolds for bioimaging application."
12/01/2011 - "This team of investigators report on functionalized fullerenes, to be used as photosensitizer for photodynamic therapy and demonstrate the efficacy of this method in an intraperitoneal carcinomatosis mouse model."
07/01/2006 - "[Oxidative properties of photoexcited fullerenes C60 and C60-containing composites in suspension of thymocytes and Ehrlich ascites carcinoma cells]."
12/01/2011 - "We tested the hypothesis that fullerenes could be used to mediate PDT of intraperitoneal (IP) carcinomatosis in a mouse model. "
12/01/2004 - "The number and vitality of cultured Ehrlich carcinoma cells or rat thymocytes were determined using tripane blue, ROS levels were registered using the methods of electron paramagnetic resonance (EPR) spectroscopy and spin traps, photoirradiation of water solution of fullerenes C(60) with visible light was carried out using mercury lamp. "
03/01/2008 - "The purpose of this study was to evaluate Fullerene as a therapeutic photosensitizer in the treatment of atherosclerosis. "
01/01/2009 - "These findings represent an important step in the hazard characterization of C60 fullerenes by showing that intraperitoneal administration is associated with a moderate decrease in the vascular function of mice with atherosclerosis."
03/01/2008 - "We conclude that infusion of a high concentration of Fullerene-PEG followed by photo-illumination resulted not in a suppression of atherosclerosis but in a progression of atherosclerosis in experimental rabbit models. "
03/01/2008 - "Is the use of fullerene in photodynamic therapy effective for atherosclerosis?"
01/01/2009 - "Modest vasomotor dysfunction induced by low doses of C60 fullerenes in apolipoprotein E knockout mice with different degree of atherosclerosis."
01/01/2014 - "Human neuroblastoma cells (SH-SY5Y) were used to evaluate the long time (24, 48 and 72 hours) effects of a fullerene hydrosoluble derivative (t3ss) as potential inhibitor of hypoxic insult. "
02/01/2011 - "Thus, we hypothesized that fullerenes could counteract the effects of OP compounds and tested this hypothesis using two in vitro test systems, hen brain and human neuroblastoma SH-SY5Y cells. "
10/14/2011 - "Here we report on the surface immobilization of redox-active fullerene derivatives and the consequent neuroprotective effects toward l-glutamate induced excitotoxicity in human derived undifferentiated neuroblastoma cells."
02/01/2011 - "No fullerene derivative at 1 μM significantly affected neuroblastoma cell viability, when determined using either Alamar Blue dye retention or a luminescent assay for ATP production. "
02/01/2011 - "Using dissipation of superoxide anion radicals as an indicator (xanthine oxidation as a positive control), all fullerene derivatives demonstrated significant antioxidant capability in neuroblastoma cells at 1 μM concentrations. "
|4.||1-Methyl-4-phenylpyridinium (1 Methyl 4 phenylpyridinium)
|7.||malonic acid (malonate)
|9.||Reactive Oxygen Species (Oxygen Radicals)
|1.||Photochemotherapy (Photodynamic Therapy)
|3.||Phototherapy (Light Therapy)